P-糖蛋白与宫颈癌顺铂化疗耐药关系及相关机制的研究进展

Relationship between P-glycoprotein and cisplatin chemotherapy resistance in cervical cancer and related mechanisms

中晚期和复发转移性宫颈癌目前最重要的治疗方式是化疗,尤以单用顺铂或以顺铂为基础的联合化疗方案为主,但随着宫颈癌细胞对化疗药物产生抵抗和耐受性,化疗耐药成为宫颈癌治疗失败的主要原因之一。如何克服宫颈癌化疗耐药是多年来临床面临的巨大挑战,其中多药耐药蛋白在影响顺铂发挥抗肿瘤的作用过程中起着重要的作用。P-糖蛋白(P-gp)属于多药耐药蛋白基因编码的一种跨膜转运蛋白质,本文对P-gp在宫颈癌顺铂化疗耐药中发挥的作用及作用机制的研究进展进行总结归纳,以期为P-gp作为治疗靶点应用于宫颈癌化疗领域添砖加瓦。

Chemotherapy is the most important treatment for advanced and recurrent metastatic cervical cancer,especially cisplatin alone or cisplatin-based combined chemotherapy.However,with the resistance and tolerance of cervical cancer cells to chemotherapy drugs,chemotherapy resistance has become one of the main reasons for the failure of treatment of cervical cancer.How to overcome chemotherapy resistance of cervical cancer is a great challenge for many years.Multidrug resistance protein plays an important role in the process of cisplatin's anti-tumor effect.P-glycoprotein(P-gp)is a transmembrane transport protein encoded by multidrug resistance protein gene.In this paper,the role of P-gp in cisplatin resistance of cervical cancer and its mechanism were summarized,in order to contribute to the application of P-gp as a therapeutic target in the field of chemotherapy of cervical cancer.